AbCellera Biologics Stock (NASDAQ:ABCL)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$3.03

52W Range

$2.33 - $6.05

50D Avg

$2.83

200D Avg

$3.20

Market Cap

$883.14M

Avg Vol (3M)

$2.31M

Beta

0.35

Div Yield

-

ABCL Company Profile

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

586

IPO Date

Dec 11, 2020

Website

ABCL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 23	Dec 22	Dec 21
Royalty	-	$443.00M	$327.30M
License	$969.00K	$696.00K	$20.78M
Milestone Payments	$1.50M	$900.00K	$8.00M
Research Fees	$35.56M	$40.80M	$19.08M

Fiscal year ends in Dec 23 | Currency in USD

ABCL Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$38.02M	$485.42M	$375.20M
Operating Income	$-237.21M	$216.51M	$204.41M
Net Income	$-146.40M	$158.52M	$153.46M
EBITDA	$-192.16M	$276.25M	$242.48M
Basic EPS	$-0.51	$0.56	$0.56
Diluted EPS	$-0.51	$0.50	$0.48

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 04, 24 | 7:22 PM

Q2 24Aug 06, 24 | 8:29 PM

Q1 24May 07, 24 | 11:00 PM

Peer Comparison

Ticker	Company
VIR	Vir Biotechnology, Inc.
PTCT	PTC Therapeutics, Inc.
SRPT	Sarepta Therapeutics, Inc.
CVAC	CureVac N.V.
KRYS	Krystal Biotech, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
IOVA	Iovance Biotherapeutics, Inc.
MDGL	Madrigal Pharmaceuticals, Inc.